Zhangjuan

Professor, doctoral supervisor, head of the department of biopharmaceutics, and head of Chinese-foreign cooperative education in pharmacy.

Professor Zhang is committed to the research in the field of tumor and autoimmune diseases, including the research and development of monoclonal antibodies, bispecific antibodies and antibody-coupled drugs (ADCs), as well as the anti-tumor immune mechanism and autoimmune disease mechanism of antibodies. Professor Zhang has undertaken many provincial and ministerial projects such as general projects of the National Natural Science Foundation of China, and carried out school-enterprise cooperation in many projects. Professor Zhang has published more than 60 SCI papers in Cancer Res, APSB, Cancer Lett and other journals as the first or correspondent author, and has been granted more than 10 national invention patents.

1. “CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer” - Published in Cancer Immunol Immunother, 2023.

2. “αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade” - Published in Cancer Immunol Immunother, 2023.

3. “Cysteine-Based Coupling: Challenges and Solutions” - Published in Bioconjug Chem, 2021.

4. “VEGFR2-targeted antibody fused with IFN α mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity” - Published in Acta Pharm Sin B, 2021.

   
   

1. Development, screening and engineering transformation of monoclonal antibody.

2. Design and research of bispecific antibody.

3. Design and evaluation of novel antibody-coupled drugs (ADCs)

4. Study on anti-tumor immune mechanism and autoimmune disease mechanism of antibody.

1. Guo Bang Belt and Road Yucai Award Postgraduate Tutor Contribution Award, 2023

2. Excellent Doctoral Thesis Supervisor of the school, 2019

3. Excellent Master Thesis Instructor in Jiangsu Province, 2018